Grail, the company that has raised $1.6 billion to develop a blood test to detect cancer early, announced Monday that it has settled on a method for its test and enrolled 115,000 patients in two large clinical trials. A third study, with 50,000 patients, has already begun.

The San Francisco-based startup, spun out of DNA sequencing giant Illumina in 2016, previously presented data on three different approaches to detect cancer using DNA circulating in the blood. One used DNA sequencing to look at specific regions of genes; a second used the technology to sequence the entire genomes of cells floating in patients’ bloodstreams; and a third looked at methylation, an epigenetic change across the whole genome.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hello,thanks for the incredible info.i was hopefully ,successfully ,treated for stage 3 tonsil cancer at md anderson in houston,8 years ago. I’m 64 years old .live in san Antonio interested in marketing this incredible revolutionary blood test.please let me know if I can assist,and save lives.sincerly,Charles r. Dodd.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy